California state regulators ordered Anthem Blue Cross Blue Shield late last week to pay providers for outstanding claims owed during the last four years. However, Anthem is pushing back and might not comply with the order.
.
The California Department of Managed Healthcare (DMHC) identified errors in claims that Anthem processed since 2007, prompting it to demand the state's largest for-profit insurer pay the outstanding amounts it owes doctors and hospitals, reported the Sacramento Business Journal
Anthem, though, says it already settled the outstanding claims with DMHC when it paid a $500,000 administrative fine as part of a settlement agreement last year.
The settlement was a result of DMHC's claims audits in 2008 after providers complained of insurers' late and inaccurate payments and inappropriate claims denials. DMHC ordered several insurers, including Anthem, to pay providers, improve their claims processes, sign settlement agreements and pay administrative fines. All insurers involved have begun paying the outstanding claims except Anthem, noted the SBJ.
Read the full story at: http://tinyurl.com/7rooa8g
Source: FierceHealthPayer
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More